Annotation Detail

Information
Associated Genes
MET
Associated Variants
MET AMPLIFICATION ( ENST00000318493.11 )
MET AMPLIFICATION ( ENST00000318493.11 )
Associated Disease
gastric adenocarcinoma
Source Database
CIViC Evidence
Description
A case-study describing a patient with MET polysomy, MET over-expression and evidence of autocrine HGF-production (the growth factor ligand of MET). The patient initially achieved a complete response on MET-Inhibitor MetMAb (Onartuzumab) for 2 years and mixed response after recurrence with resistance in some of the newly developing metastases.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/689
Gene URL
https://civic.genome.wustl.edu/links/genes/52
Variant URL
https://civic.genome.wustl.edu/links/variants/270
Rating
3
Evidence Type
Predictive
Disease
Gastric Adenocarcinoma
Evidence Direction
Supports
Drug
Onartuzumab
Evidence Level
C
Clinical Significance
Sensitivity/Response
Pubmed
22389872
Drugs
Drug NameSensitivitySupported
OnartuzumabSensitivitytrue